Leonardo Furi
University of Siena
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Leonardo Furi.
Nature Communications | 2014
Ana Sousa Manso; Melissa H. Chai; John M. Atack; Leonardo Furi; Megan De Ste Croix; Richard D. Haigh; Claudia Trappetti; Abiodun D. Ogunniyi; Lucy K. Shewell; Matthew Boitano; Tyson A. Clark; Jonas Korlach; Matthew Blades; Evgeny M. Mirkes; Alexander N. Gorban; James C. Paton; Michael P. Jennings; Marco R. Oggioni
Streptococcus pneumoniae (the pneumococcus) is the world’s foremost bacterial pathogen in both morbidity and mortality. Switching between phenotypic forms (or ‘phases’) that favour asymptomatic carriage or invasive disease was first reported in 1933. Here, we show that the underlying mechanism for such phase variation consists of genetic rearrangements in a Type I restriction-modification system (SpnD39III). The rearrangements generate six alternative specificities with distinct methylation patterns, as defined by single-molecule, real-time (SMRT) methylomics. The SpnD39III variants have distinct gene expression profiles. We demonstrate distinct virulence in experimental infection and in vivo selection for switching between SpnD39III variants. SpnD39III is ubiquitous in pneumococci, indicating an essential role in its biology. Future studies must recognize the potential for switching between these heretofore undetectable, differentiated pneumococcal subpopulations in vitro and in vivo. Similar systems exist in other bacterial genera, indicating the potential for broad exploitation of epigenetic gene regulation.
Antimicrobial Agents and Chemotherapy | 2013
Leonardo Furi; Maria Laura Ciusa; Daniel R. Knight; Valeria Di Lorenzo; Nadia Tocci; Daniela Cirasola; Lluis Aragones; Joana Rosado Coelho; Ana T. Freitas; Emmanuela Marchi; Laura Moce; Pilar Visa; John Blackman Northwood; Carlo Viti; Elisa Borghi; Graziella Orefici; Ian Morrissey; Marco R. Oggioni
ABSTRACT The MICs and minimum bactericidal concentrations (MBCs) for the biocides benzalkonium chloride and chlorhexidine were determined against 1,602 clinical isolates of Staphylococcus aureus. Both compounds showed unimodal MIC and MBC distributions (2 and 4 or 8 mg/liter, respectively) with no apparent subpopulation with reduced susceptibility. To investigate further, all isolates were screened for qac genes, and 39 of these also had the promoter region of the NorA multidrug-resistant (MDR) efflux pump sequenced. The presence of qacA, qacB, qacC, and qacG genes increased the mode MIC, but not MBC, to benzalkonium chloride, while only qacA and qacB increased the chlorhexidine mode MIC. Isolates with a wild-type norA promoter or mutations in the norA promoter had similar biocide MIC distributions; notably, not all clinical isolates with norA mutations were resistant to fluoroquinolones. In vitro efflux mutants could be readily selected with ethidium bromide and acriflavine. Multiple passages were necessary to select mutants with biocides, but these mutants showed phenotypes comparable to those of mutants selected by dyes. All mutants showed changes in the promoter region of norA, but these were distinct from this region of the clinical isolates. Still, none of the in vitro mutants displayed fitness defects in a killing assay in Galleria mellonella larvae. In conclusion, our data provide an in-depth comparative overview on efflux in S. aureus mutants and clinical isolates, showing also that plasmid-encoded efflux pumps did not affect bactericidal activity of biocides. In addition, current in vitro tests appear not to be suitable for predicting levels of resistance that are clinically relevant.
Expert Review of Anti-infective Therapy | 2013
Marco R. Oggioni; Leonardo Furi; Joana Rosado Coelho; Jean-Yves; José L. Martínez
Workshop on biocides: do they select for antimicrobial resistance? Second International Conference on Antimicrobial Research Lisbon, Portugal, 21–23 November 2012. Interconnection between microbial resistance to biocides and antibiotics is a topic of increasing interest given the recent changes in European legislation and claims of a risk of biocide use on bacterial resistance. In the second International Conference on Antimicrobial Research held in Lisbon in November 2012, a workshop specifically addressed this topic, presentations included approaches to risk assessment and investigations into the molecular mechanisms of biocide resistance and co- and cross-resistance to antibiotics. The overall conclusion was that, even if each biocide represents a specific case, there is scientific evidence that biocides select for biocide resistance, but that there is, so far, no conclusive evidence that this also determined or will determine an increase in antibiotic resistance.
PLOS Pathogens | 2014
Alice Gerlini; Leonarda Colomba; Leonardo Furi; Tiziana Braccini; Ana Sousa Manso; Andrea Pammolli; Bo Wang; Antonio Vivi; Maria Tassini; Nico van Rooijen; Gianni Pozzi; Susanna Ricci; Peter W. Andrew; Uwe Koedel; E. Richard Moxon; Marco R. Oggioni
The pathogenesis of bacteraemia after challenge with one million pneumococci of three isogenic variants was investigated. Sequential analyses of blood samples indicated that most episodes of bacteraemia were monoclonal events providing compelling evidence for a single bacterial cell bottleneck at the origin of invasive disease. With respect to host determinants, results identified novel properties of splenic macrophages and a role for neutrophils in early clearance of pneumococci. Concerning microbial factors, whole genome sequencing provided genetic evidence for the clonal origin of the bacteraemia and identified SNPs in distinct sub-units of F0/F1 ATPase in the majority of the ex vivo isolates. When compared to parental organisms of the inoculum, ex-vivo pneumococci with mutant alleles of the F0/F1 ATPase had acquired the capacity to grow at low pH at the cost of the capacity to grow at high pH. Although founded by a single cell, the genotypes of pneumococci in septicaemic mice indicate strong selective pressure for fitness, emphasising the within-host complexity of the pathogenesis of invasive disease.
Current Pharmaceutical Design | 2015
Marco R. Oggioni; Joana Rosado Coelho; Leonardo Furi; Daniel R. Knight; Carlo Viti; Graziella Orefici; J. L. Martinez; Ana T. Freitas; Teresa M. Coque; Ian Morrissey
There is a growing concern by regulatory authorities for the selection of antibiotic resistance caused by the use of biocidal products. We aimed to complete the detailed information on large surveys by investigating the relationship between biocide and antibiotic susceptibility profiles of a large number of Staphylococcus aureus isolates using four biocides and antibiotics commonly used in clinical practice. The minimal inhibitory concentration (MIC) for most clinically-relevant antibiotics was determined according to the standardized methodology for over 1600 clinical S. aureus isolates and compared to susceptibility profiles of benzalkonium chloride, chlorhexidine, triclosan, and sodium hypochlorite. The relationship between antibiotic and biocide susceptibility profiles was evaluated using non-linear correlations. The main outcome evidenced was an absence of any strong or moderate statistically significant correlation when susceptibilities of either triclosan or sodium hypochlorite were compared for any of the tested antibiotics. On the other hand, correlation coefficients for MICs of benzalkonium chloride and chlorhexidine were calculated above 0.4 for susceptibility to quinolones, beta-lactams, and also macrolides. Our data do not support any selective pressure for association between biocides and antibiotics resistance and furthermore do not allow for a defined risk evaluation for some of the compounds. Importantly, our data clearly indicate that there does not involve any risk of selection for antibiotic resistance for the compounds triclosan and sodium hypochlorite. These data hence infer that biocide selection for antibiotic resistance has had so far a less significant impact than feared.
Antimicrobial Agents and Chemotherapy | 2012
Marco R. Oggioni; Maria Laura Ciusa; Leonardo Furi; Lucilla Baldassarri; Graziella Orefici; Daniela Cirasola; José L. Martínez; Ian Morrissey; Elisa Borghi
phenotypes and virulence potential (3). Phenotypiccharacterization was carried out on one mutant (P10) that hadbeenpassaged10timesinatriclosangradient.MutantP10exhib-itedmultiplephenotypes,includingsmallcolonysize,slowplank-tonic growth, impaired biofilm formation, impaired hemolyticactivity, impaired coagulase activity, and impaired virulence, in amodel of
Microbiological Research | 2015
Emmanuela Marchi; Leonardo Furi; Stefania Arioli; Ian Morrissey; Valeria Di Lorenzo; Diego Mora; Luciana Giovannetti; Marco R. Oggioni; Carlo Viti
Staphylococcus aureus strains harboring QacA, QacB, QacC, QacG transporters and norA promoter up-regulating mutations were characterized by phenotype microarray (PM), standard methods for susceptibility testing, and ethidium bromide efflux assays, in order to increase knowledge on phenotypes associated to efflux pumps and their substrates. PM data and standard susceptibility testing lead to the identification of new potential efflux targets, such as guanidine hydrochloride or 8-hydroxyquinoline for QacA and QacC pumps, respectively. The identification of compounds to which the presence of efflux pumps induced increased susceptibility opens new perspectives for potential adjunct anti-resistance treatment (i.e. strains bearing QacB transporters showed increased susceptibility to thioridazine, amitriptyline and orphenadrine). Although the tested isolates were characterized by high degree of heterogeneity, a hallmark of clinical isolates, direct ethidium bromide efflux assays were effective in highlighting differences in efflux efficiency among strains. These data add to characterization of substrate specificity in the different classes of staphylococcal multidrug efflux systems conferring specific substrate profiles and efflux features to each of them.
Desalination and Water Treatment | 2014
Aybala Koc; Kemal B. Orhon; Abdullah Ogutverici; Levent Yilmaz; Leonardo Furi; Marco R. Oggioni; Filiz B. Dilek; Ulku Yetis
AbstractThis paper examines the effect of adsorption of Triclosan (TCS) onto labware on the results obtained during lab-scale experiments. Three sets of experiments were considered; two of them expose the problem in water or wastewater treatability studies and the other one in microbial susceptibility testings. In the former two sets, lab-scale systems; ozonation; and membrane filtration (NF/RO) that are commonly used in water or wastewater treatability studies were utilized and the distribution of TCS within the systems were followed. The ozonation labware tested was composed of a Pyrex reactor with plastic and glass tubings. The NF/RO system was composed of a stainless steel feed tank, a stainless steel membrane unit, stainless steel flanges, and stainless steel and plastic tubings. Ozonation system was operated without ozone gas, but air. Similarly, NF/RO system was without membrane in it. Both of the systems were rinsed with methanol before experiments to remove any possible earlier contamination. Dur...
BMC Genomics | 2015
Denis Grandgirard; Leonardo Furi; Maria Laura Ciusa; Lucilla Baldassarri; Daniel R. Knight; Ian Morrissey; Carlo R. Largiadèr; Stephen L. Leib; Marco R. Oggioni
BackgroundThe enoyl-acyl carrier protein (ACP) reductase enzyme (FabI) is the target for a series of antimicrobial agents including novel compounds in clinical trial and the biocide triclosan. Mutations in fabI and heterodiploidy for fabI have been shown to confer resistance in S. aureus strains in a previous study. Here we further determined the fabI upstream sequence of a selection of these strains and the gene expression levels in strains with promoter region mutations.ResultsMutations in the fabI promoter were found in 18% of triclosan resistant clinical isolates, regardless the previously identified molecular mechanism conferring resistance. Although not significant, a higher rate of promoter mutations were found in strains without previously described mechanisms of resistance. Some of the mutations identified in the clinical isolates were also detected in a series of laboratory mutants. Microarray analysis of selected laboratory mutants with fabI promoter region mutations, grown in the absence of triclosan, revealed increased fabI expression in three out of four tested strains. In two of these strains, only few genes other than fabI were upregulated. Consistently with these data, whole genome sequencing of in vitro selected mutants identified only few mutations except the upstream and coding regions of fabI, with the promoter mutation as the most probable cause of fabI overexpression. Importantly the gene expression profiling of clinical isolates containing similar mutations in the fabI promoter also showed, when compared to unrelated non-mutated isolates, a significant up-regulation of fabI.ConclusionsIn conclusion, we have demonstrated the presence of C34T, T109G, and A101C mutations in the fabI promoter region of strains with fabI up-regulation, both in clinical isolates and/or laboratory mutants. These data provide further observations linking mutations upstream fabI with up-regulated expression of the fabI gene.
International Journal of Antimicrobial Agents | 2012
Maria Laura Ciusa; Leonardo Furi; Daniel R. Knight; Francesca Decorosi; Marco Fondi; Carla Raggi; Joana Rosado Coelho; Luis Aragones; Laura Moce; Pilar Visa; Ana T. Freitas; Lucilla Baldassarri; Renato Fani; Carlo Viti; Graziella Orefici; José L. Martínez; Ian Morrissey; Marco R. Oggioni